FDA told Newman Clinic its website misbranded compounded semaglutide and tirzepatide with false and misleading claims.
What happened
FDA reviewed the Newman Clinic website at https://www.newmanclinic.com in December 2025 and found it offers compounded semaglutide and tirzepatide drug products. The pictured product labels show "Newman Clinic," suggesting the clinic compounds the drugs when it does not. The site also claims the products are the "Same Ingredient as Ozempic® and Wegovy®" and "Same Ingredient as Mounjaro® and Zepbound®," which imply FDA approval the products do not have.
What FDA found
The website labels name "Newman Clinic" in a way that suggests the clinic made the drugs, when it did not.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]; 21 CFR 201.1(h)(2)The claim "Same Ingredient as Ozempic® and Wegovy®" falsely implies the compounded product is FDA-approved.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The claim "Same Ingredient as Mounjaro® and Zepbound®" falsely implies the compounded product is FDA-approved.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]Sending misbranded drugs across state lines is a prohibited act.
FDCA § 301(a) [21 U.S.C. § 331(a)]Compounded drugs must meet the conditions of sections 503A or 503B to be exempt from the new drug approval requirements.
FDCA §§ 503A, 503B [21 U.S.C. §§ 353a, 353b]
What FDA wants
Within 15 working days, send a written response to the Office of Compounding Quality and Compliance describing the steps taken to fix the violations and prevent them from recurring. Include who makes the compounded products, a sample of their labeling, and how the misleading website claims were corrected or why they are accurate.
Who should pay attention
- telehealth clinics that market compounded semaglutide or tirzepatide
- compounders whose products are sold through clinic websites
- clinics that compare their products to FDA-approved brand drugs by name
This is a summary. Read the original letter on fda.gov.